Blow to Novartis as NICE rejects migraine drug Aimovig again

After NICE rejected Novartis’ migraine prevention drug Aimovig in draft guidance issued in January, it was inundated with comments that forced a delay to its final appraisal document. That’s now out – and the answer is still no.